Kite Pharma - A Gilead Company In The NEWS Gilead Sciences' (GILD) firm Kite Pharma, announced that the European Commission (EC) has approved its CAR T-cell therapy Yescarta® (axicabtagene ciloleucel) for adult patients with relapsed or refractory follicular lymphoma (FL) after three or more lines of systemic therapy. Yescarta maintained its orphan medicinal product designation in this indication. From . . . This content is for …

Akero Therapeutics Financing Transactions Akero Therapeutics (AKRO) is one of the selected firms for the Prohost Portfolio. The firm is clinical-stage and develops treatments for metabolic diseases marked by high . . . This content is for paid subscribers. Please click here to subscribe or here to log in.

The Great News from Amylyx Pharmaceuticals On Jun. 13, 2022, Amylyx Pharmaceuticals (AMLX) announced that Health Canada has approved ALBRIOZA (sodium phenylbutyrate and ursodoxicoltaurine), with conditions, for amyotrophic lateral sclerosis (ALS). The important thing to learn from Amylyx Pharmaceuticals' press release is that the clinical data demonstrated a . . . This content is for paid subscribers. Please click here to subscribe or here to log in.

Inflation and the Stock Market Inflation, which we were told was but a temporary passing phenomenon, has reached its maximum peak in four decades. We must not get anxious about this inflation, a well-known enemy to the economy and a catastrophe for the citizens, that has yet to be accused, by the professionals and the media, of harming the economy. We knew. Now, the stock …

Bristol-Myers Squibb Product Deucravacitinib Bristol-Myers Squibb (BMY) product deucravacitinib has demonstrated positive results from the Phase 2 PAISLEY study in comparison to placebo in patients with moderate to severe systemic lupus erythematosus (SLE). The study met the primary endpoint. Deucravacitinib is an oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor. The product has a unique mechanism of . . . This content is for paid …